BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32354656)

  • 21. New pathogenic germline variants identified in mesothelioma.
    Belcaid L; Bertelsen B; Wadt K; Tuxen I; Spanggaard I; Højgaard M; Benn Sørensen J; Ravn J; Lassen U; Cilius Nielsen F; Rohrberg K; Westmose Yde C
    Lung Cancer; 2023 May; 179():107172. PubMed ID: 36944283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
    Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
    J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethnic disparities among men with prostate cancer undergoing germline testing.
    Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
    Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants.
    Mezina A; Philips N; Bogus Z; Erez N; Xiao R; Fan R; Olthoff KM; Reddy KR; Samadder NJ; Nielsen SM; Hatchell KE; Esplin ED; Rustgi AK; Katona BW; Hoteit MA; Nathanson KL; Wangensteen KJ
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    Yadav S; Hu C; Hart SN; Boddicker N; Polley EC; Na J; Gnanaolivu R; Lee KY; Lindstrom T; Armasu S; Fitz-Gibbon P; Ghosh K; Stan DL; Pruthi S; Neal L; Sandhu N; Rhodes DJ; Klassen C; Peethambaram PP; Haddad TC; Olson JE; Hoskin TL; Goetz MP; Domchek SM; Boughey JC; Ruddy KJ; Couch FJ
    J Clin Oncol; 2020 May; 38(13):1409-1418. PubMed ID: 32125938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
    DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
    Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
    Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
    Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
    Carlo MI; Ravichandran V; Srinavasan P; Bandlamudi C; Kemel Y; Ceyhan-Birsoy O; Mukherjee S; Mandelker D; Chaim J; Knezevic A; Rana S; Fnu Z; Breen K; Arnold AG; Khurram A; Tkachuk K; Cipolla CK; Regazzi A; Hakimi AA; Al-Ahmadie H; Dalbagni G; Cadoo KA; Walsh MF; Teo MY; Funt SA; Coleman JA; Bochner BH; Iyer G; Solit DB; Stadler ZK; Zhang L; Rosenberg JE; Taylor BS; Robson ME; Berger MF; Vijai J; Bajorin DF; Offit K
    J Clin Oncol; 2020 Feb; 38(5):406-414. PubMed ID: 31794323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
    Mossanen M; Nassar AH; Stokes SM; Martinez-Chanza N; Kumar V; Nuzzo PV; Kwiatkowski DJ; Garber JE; Curran C; Freeman D; Preston M; Mouw KW; Kibel A; Choueiri TK; Sonpavde G; Rana HQ
    Clin Genitourin Cancer; 2022 Dec; 20(6):568-574. PubMed ID: 36127252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
    Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
    Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study.
    Tavano F; Gioffreda D; Fontana A; Palmieri O; Gentile A; Latiano T; Latiano A; Latiano TP; Scaramuzzi M; Maiello E; Bazzocchi F; Perri F
    Mol Med; 2023 Jan; 29(1):14. PubMed ID: 36717774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.
    Murali K; Dwarte TM; Nikfarjam M; Tucker KM; Vaughan RB; Efthymiou M; Collins A; Spigelman AD; Salmon L; Johns AL; Williams DB; Delatycki MB; John T; Stoita A
    Hered Cancer Clin Pract; 2021 Aug; 19(1):33. PubMed ID: 34399810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients.
    Baz M; Gondran-Teiller V; Bressac B; Cabaret O; Fievet A; Dimaria M; Goldbarg V; Colas C; Bonnet-Dupeyron MN; Tinat J; Lebrun M; Mari V; Limacher JM; Corsini C; Ginglinger E; Saurin JC; Brahimi A; Rouzier C; Giraud S; Schuster H; Hollebecque A; Boige V; Cauchin E; Malka D; Caron O; Rouleau E
    Dig Dis Sci; 2023 Apr; 68(4):1525-1528. PubMed ID: 36315333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.